Login     Register  
    Home  |   Your Profile  |   Search  |   About Us  |   Disclaimer  |   Pricing  |   Participating on CanBiotech
Can Biotech - BioPharma Portal and B2B Marketplace DoveBid: Biopharma Auctions
Site Search:
    Home CanBiotech™ Innovations Careers Partnerships Asia Directory Events News Innovation Community BioInnovation Webinars
 Event Advertisers   Show all: Event Advertisers

Click here to subscribe to Can Biotech Newsletters

 My Links   Show all: My Links

 CanBiotech News   Show all: CanBiotech News

 Investor: Alliances   Show all: Investor: Alliances

 Biopharma News in Asia   Show all: Biopharma News in Asia

 Innovation Blogs and News   Show all: Innovation Blogs and News


Innovate ABQ
June 2014

Innovate ABQ brings together the research power of the state's flagship university with Albuquerque's entrepreneurial and established business community to create new companies, grow existing ones and attract more out-of-state business.

Sharing Clinical Data: A Paradigm Change
June 2014

Pharmaceutical companies are now seeing the benefits of sharing clinical trial or patient data to create a pool of data-allowing for the emergence of patterns which might assist further studies.
Read More..

Infographic: Is Scientific Collaboration Broken?
June 2014

The people at Science Exchange surveyed over 1,500 scientists about their collaborations. This infographic summarizes the enlightening data they garnered.

Pfizer's New Hub in Cambridge, MA
June 2014

Pfizer just opened its newest R&D facility in Cambridge, MA. Mikael Dolsten, Pfizer’s president of worldwide research and development, said in a statement that “Having all of our Cambridge-area researchers working closely together in one of the world’s most exciting biomedical ecosystems will allow us to continue our efforts to grow our external collaborations and has the potential to help speed the translation of scientific knowledge into potential medical breakthroughs across areas of unmet need such as lupus, inflammatory bowel disease, kidney disease, type 2 diabetes, muscular dystrophy and Parkinson's disease.”

Pooling Resources, Targeted Clinical Trials
May 2014

The public and private sectors are increasingly pooling resources. For example, under the Accelerating Medicines Partnership, the NIH and ten biopharmaceutical companies will fund a five-year effort to validate promising targets in three disease areas. In cancer research the goal is to test multiple therapies in a single trial and identify the most responsive patients.

AstraZeneca turns to Open Innovation
May 2014

Astra has developed partnerships with health charities, academic researchers and even its competitors. The collaborations include the sharing of early-stage research with mutual knowledge usage rights.

A Three Part Open Innovation Model-Joining Assets
April 2014
GlaxoSmithKline plc announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses.
From joint venture, to acquisition and divestment, learn more about this transaction.

Join us on May 14th at 9:00am Pacific Time for our next webinar event as Academic Director, Robert Sutton, discusses how to scale innovation without screwing up.

PCORI App Challenge
April 2014

The Patient-Centered Outcomes Research Institute (PCORI) was authorized in 2010 by the Patient Protection and Affordable Care Act to help patients make better-informed health and health care decisions, and improve healthcare delivery and outcomes, by producing and promoting high-integrity, evidence-based information.

The Successes and Challengs of Open Source Biopharmaceutical Innovation
April 2014

Journal coverIncreasingly, open-source–based alliances seek to provide broad access to data, research-based tools, preclinical samples and downstream compounds. The challenge is how to create value from open-source biopharmaceutical innovation. This value creation may occur via transparency and usage of data across the biopharmaceutical value chain as stakeholders move dynamically between open source and open innovation.
It is the author’s opinion that the assessment of when and how value creation will occur, through open-source biopharmaceutical innovation, is paramount. The key is to determine the metrics of value creation and the necessary technological, educational and legal frameworks to support the downstream outcomes of now big data-based open-source initiatives. The continued focus on the early-stage value creation is not advisable. Instead, it would be more advisable to adopt an approach where stakeholders transform open-source initiatives into open-source discovery, crowdsourcing and open product development partnerships on the same platform.
Read More: http://informahealthcare.com/doi/abs/10.1517/17460441.2014.905539?af=R

Encouraging Pharmaceutical Innovation in Middle-Income Countries

The opportunity to develop innovative activities from basic research through to clinical development varies from country to country. To be successful, a jigsaw of policies is needed, including a coordinated industrial and health policy, strong IP protection and an environment that encourages partnerships among the different stakeholders.

Innovation Capacity Development
Business Innovations at the Base of the Pyramid: A Breakout Session

The 4.5 billion people in the world at "the base of the pyramid" (who live on $5 per day or less) represent a $15 trillion economy. Panelists describe their ventures at the base of the pyramid and respond to a range of questions from attendees.

Globalization of Innovation and R&D: A Breakout Session
Panelists describe how their organizations benefit from a global approach to innovation, and how they cope with innovation-related challenges.

Continuing Reading More Innovation News and Blogs...

Using the Site Privacy & Security Statement 
Advertise with us Directory Guide & Access Policy
Event Postings CanBiotech Newsletters

© 2000-2014 CanBiotech™ Inc.